<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Qual Life Outcomes</journal-id><journal-id journal-id-type="iso-abbrev">Health Qual Life Outcomes</journal-id><journal-title-group><journal-title>Health and Quality of Life Outcomes</journal-title></journal-title-group><issn pub-type="epub">1477-7525</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29394942</article-id><article-id pub-id-type="pmc">5797407</article-id><article-id pub-id-type="publisher-id">848</article-id><article-id pub-id-type="doi">10.1186/s12955-018-0848-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Report</subject></subj-group></article-categories><title-group><article-title>Factors influencing health-related quality of life in patients with Type 1 diabetes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Raymakers</surname><given-names>A. J. N.</given-names></name><address><email>adam.raymakers@nuigalway.ie</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gillespie</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Hara</surname><given-names>M. C.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Griffin</surname><given-names>M. D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dinneen</surname><given-names>S. F.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0488 0789</institution-id><institution-id institution-id-type="GRID">grid.6142.1</institution-id><institution>C&#x000da;RAM Centre for Research in Medical Devices, National University of Ireland Galway, </institution></institution-wrap>Galway, Ireland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0488 0789</institution-id><institution-id institution-id-type="GRID">grid.6142.1</institution-id><institution>Health Economics and Policy Analysis Centre, National University of Ireland Galway, </institution></institution-wrap>Galway, Ireland </aff><aff id="Aff3"><label>3</label>Research and Development, Health Services Executive, Health and Wellbeing Division, Galway, Ireland </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0488 0789</institution-id><institution-id institution-id-type="GRID">grid.6142.1</institution-id><institution>School of Medicine, Clinical Science Institute, National University of Ireland Galway, </institution></institution-wrap>Galway, Ireland </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0617 9371</institution-id><institution-id institution-id-type="GRID">grid.412440.7</institution-id><institution>Endocrinology and Diabetes Centre, Galway University Hospital, </institution></institution-wrap>Galway, Ireland </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>16</volume><elocation-id>27</elocation-id><history><date date-type="received"><day>16</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Aims</title><p id="Par1">Generic, preference-based measures of health-related quality of life (HRQoL) are a common input to the economic evaluation of new health&#x000a0;technologies. As such, it is important to explore what characteristics of patients with Type 1 diabetes might impact scores on such measures.</p></sec><sec><title>Methods</title><p id="Par2">This study utilizes baseline data from a cluster-randomized trial that recruited patients with Type 1 diabetes at six centers across Ireland. Health-related quality of life was assessed using the three-level EuroQol EQ-5D (EQ-5D) measure. Patients&#x02019; responses to individual dimensions of the EQ-5D were explored. To see which patient factors influenced EQ-5D scores, multivariate regression analysis was conducted with EQ-5D scores as the outcome variable.</p></sec><sec><title>Results</title><p id="Par3">Data was available for 437 Type 1 diabetes patients. The median age of these patients was 40 (IQR: 31-49) years and 53.8% were female. Overall, patients reported a high HRQoL based on EQ-5D scores (0.87 (SD: 0.19). Fifty-four percent of patients reported a perfect HRQoL. For those that reported problems, the most common dimension was the anxiety/depression dimension of the EQ-5D (29.6%). In the multivariate regression analysis, self-reported mental illness (&#x02212;&#x02009;0.22 (95% CI: -0.34, &#x02212;&#x02009;0.10)) and being unemployed (&#x02212;&#x02009;0.07 (95% CI: -0.13, &#x02212;&#x02009;0.02)) were negatively associated with EQ-5D scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). The influence of self-reported mental illness was persistent in sensitivity analyses.</p></sec><sec><title>Conclusions</title><p id="Par4">The study results indicate that patients with Type 1 diabetes report a high HRQoL based on responses to the EQ-5D. However, there are a substantial number of Type 1 diabetes patients that report problems in the anxiety/depression dimension, which may provide avenues to improve patients&#x02019; HRQoL.</p></sec><sec><title>Trial registration</title><p id="Par5">Current Controlled Trials <ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN79759174">ISRCTN79759174</ext-link>.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s12955-018-0848-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><funding-group><award-group><funding-source><institution>Health Research Board (IE)</institution></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001602</institution-id><institution>Science Foundation Ireland</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution>European Regional Development Fund</institution></funding-source><award-id>13/RC/2073</award-id><principal-award-recipient><name><surname>Raymakers</surname><given-names>A. J. N.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par15">The global incidence of Type 1 diabetes has been rising and is predicted to further increase in the foreseeable future [<xref ref-type="bibr" rid="CR1">1</xref>]. Commensurate with this increase is the development and availability of new technologies for the monitoring and treatment of the disease [<xref ref-type="bibr" rid="CR2">2</xref>]. Emerging technologies will need to demonstrate their relative value, compared to existing technologies, in order to be reimbursed by the relevant body. Economic evaluation is a method for making such comparisons, whereby the costs and benefits of new technologies, compared to the standard of care, are simultaneously considered [<xref ref-type="bibr" rid="CR3">3</xref>]. Generic, preference-based measures of health-related quality of life (HRQoL) are often used to assess these benefits in economic evaluation and, thus, play a key role in the reimbursement of health interventions. As such, it is important to understand factors that might influence patients&#x02019; scores on these measures.</p><p id="Par16">Existing literature for patients with Type 2 diabetes has found that obesity and the presence of diabetes-related complications were significant factors in determining patients EQ-5D scores [<xref ref-type="bibr" rid="CR4">4</xref>]. For women with gestational diabetes, Danyliv et al. [<xref ref-type="bibr" rid="CR5">5</xref>] found no statistically significant associations with patient characteristics and EQ-5D scores, aside from smoking status (specifically, being a previous smoker). In a study population of patients with Type 1 diabetes between 8 and 17&#x000a0;years of age, a significant association was estimated between poor glycemic control with both depression and HRQoL [<xref ref-type="bibr" rid="CR6">6</xref>]. Poor glycemic control [<xref ref-type="bibr" rid="CR7">7</xref>] and hyperglycemic symptoms [<xref ref-type="bibr" rid="CR8">8</xref>] were also associated with reduced HRQoL, measured using the EQ-5D in adult patients, even after adjustment for diabetes-related complications [<xref ref-type="bibr" rid="CR9">9</xref>]. Similar to results reported in patients with Type 2 diabetes, previous evidence suggests that diabetes-related complications are significantly and negatively related to EQ-5D index scores in adults with Type 1 diabetes [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par18">Therefore, the objective of this study is to explore associations between those factors that influence HRQoL, as measured by the EQ-5D and EQ-VAS, in patients with Type 1 diabetes.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par19">This study used baseline data from the Irish Dose&#x000a0;Adjustment for Normal Eating (DAFNE) cluster-randomized trial which compared structured curriculum-based&#x000a0;group education follow-up with&#x000a0;individual follow-up for patients with Type 1 diabetes. Full details are the trial are reported in the study protocol [<xref ref-type="bibr" rid="CR11">11</xref>], clinical study [<xref ref-type="bibr" rid="CR12">12</xref>], and cost-effectiveness analysis [<xref ref-type="bibr" rid="CR13">13</xref>] Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p><sec id="Sec3"><title>Health-related quality of life measurement</title><p id="Par20">For this study, the outcomes of interest are the 3-level version of the&#x000a0;EuroQol 5-dimension instrument (hereafter, the&#x000a0;&#x02018;EQ-5D&#x02019;), and the secondary outcome, the EuroQol Visual Analogue Scale (EQ-VAS). The EQ-VAS accompanies the EQ-5D questionnaire and is a visual analogue scale for which respondents are directed to indicate their perceived HRQoL on that particular day (scale 0-100). The EQ-5D is a generic, preference-based measure of HRQoL consisting of five dimensions, each with three levels [<xref ref-type="bibr" rid="CR14">14</xref>]. These five dimensions include: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three effective levels: no problems, some problems, extreme problems. The EQ-5D responses were then used to compute a utility score which ranges from &#x02212;&#x02009;0.594 to 1. Where &#x02018;1&#x02019; represents a state of &#x02018;perfect&#x02019; health, &#x02018;0&#x02019; is equal to death, and health states below &#x02018;0&#x02019; are considered to be worse than death [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec4"><title>Statistical analysis</title><p id="Par21">We examined the distribution of EQ-5D index scores and EQ-VAS scores which revealed a skewed distribution for the EQ-5D scores, similar to what has been reported elsewhere [<xref ref-type="bibr" rid="CR16">16</xref>]. EQ-VAS scores approximated a normal distribution. Univariate linear regression analyses were conducted using EQ-5D&#x000a0;index scores and EQ-VAS scores as the outcome variable. Covariates were included in the multivariate model using a threshold of inclusion of <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.2 in these univariate models. Due to distributional concerns about EQ-5D scores, and concerns about the interpretability of results in a linear regression framework, we estimated the linear regression models using robust standard errors (also known as White-Huber standard errors) [<xref ref-type="bibr" rid="CR17">17</xref>]. A sensitivity analysis was also performed, given these distributional concerns with EQ-5D scores, whereby a binary outcome variable was created for those reporting &#x02018;any problems&#x02019; and those reporting &#x02018;no problems&#x02019; in EQ-5D scores to explore whether the same associations existed in a logistic regression framework. Finally, we explored individual domain scores to determine whether covariates were significantly associated with specific domains of the EQ-5D, again by collapsing the responses into &#x02018;any problems&#x02019; and &#x02018;no problems&#x02019;. All analyses were conducted using the statistical package &#x02018;R&#x02019; (version 3.2.3).</p></sec></sec><sec id="Sec5"><title>Results</title><p id="Par22">This trial consisted of 437 patients with Type 1 diabetes from 6 centres across Ireland&#x000a0;(including one site in Northern Ireland). The median age of these patients was 40 (IQR: 31-49) and 53.8% were female. Further details of the study patients are available in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Fifty-four percent of patients reported themselves as being in perfect health based on the EQ-5D index&#x000a0;score. Only one patient reported a value of less than 0. The mean EQ-5D score and mean EQ-VAS score were 0.87 (SD: 0.19) and 71.5 (SD: 16.8), respectively.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the study participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Value</th></tr></thead><tbody><tr><td>Age</td><td>40.8 (SD: 11.7)</td></tr><tr><td>Female</td><td>235 (53.8%)</td></tr><tr><td>Completed 3rd Level Education</td><td>178 (48.0%)</td></tr><tr><td>Single</td><td>142 (37.6%)</td></tr><tr><td>Employed</td><td>297 (78.4%)</td></tr><tr><td>Smoking History<sup>a</sup></td><td>174 (45.6%)</td></tr><tr><td>Body Mass Index (BMI)&#x000a0;kg/m<sup>2</sup></td><td>26.0 (SD: 4.1)</td></tr><tr><td>Years Since Diagnosis</td><td>15.9 (SD: 10.8)</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>8.3% (SD: 1.4)</td></tr><tr><td>HbA<sub>1c</sub> (mmol/mol)</td><td>67 (SD: 8)</td></tr><tr><td>Systolic BP&#x000a0;mg/Hg</td><td>124.9 (SD: 18.9)</td></tr><tr><td>Diastolic BP&#x000a0;mg/Hg</td><td>74.1 (SD: 10.9)</td></tr><tr><td>Complications<sup>a</sup></td><td>93 (21.4%)</td></tr><tr><td>EQ-VAS<sup>b</sup></td><td>71.5 (SD: 16.8)</td></tr><tr><td>EQ-5D<sup>c</sup></td><td>0.87 (SD: 0.19)</td></tr><tr><td colspan="2">Individual Dimensions of the EQ-5D</td></tr><tr><td>&#x02003;Mobility</td><td/></tr><tr><td>&#x02003;&#x02003;No Problems</td><td>392 (89.7%)</td></tr><tr><td>&#x02003;&#x02003;Some Problems</td><td>35 (8.0%)</td></tr><tr><td>&#x02003;&#x02003;Extreme Problems</td><td>0 (0%)</td></tr><tr><td colspan="2">&#x02003;Self-Care</td></tr><tr><td>&#x02003;&#x02003;No Problems</td><td>416 (95.2%)</td></tr><tr><td>&#x02003;&#x02003;Some Problems</td><td>7 (1.6%)</td></tr><tr><td>&#x02003;&#x02003;Extreme Problems</td><td>0 (0%)</td></tr><tr><td colspan="2">&#x02003;Usual Activities</td></tr><tr><td>&#x02003;&#x02003;No Problems</td><td>354 (81.0%)</td></tr><tr><td>&#x02003;&#x02003;Some Problems</td><td>70 (16.3%)</td></tr><tr><td>&#x02003;&#x02003;Extreme Problems</td><td>3 (0.7%)</td></tr><tr><td colspan="2">&#x02003;Pain/Discomfort</td></tr><tr><td>&#x02003;&#x02003;No Problems</td><td>335 (78.3%)</td></tr><tr><td>&#x02003;&#x02003;Some Problems</td><td>81 (18.9%)</td></tr><tr><td>&#x02003;&#x02003;Extreme Problems</td><td>10 (2.3%)</td></tr><tr><td colspan="2">&#x02003;Anxiety/Depression</td></tr><tr><td>&#x02003;&#x02003;No Problems</td><td>295 (70.4%)</td></tr><tr><td>&#x02003;&#x02003;Some Problems</td><td>118 (28.2%)</td></tr><tr><td>&#x02003;&#x02003;Extreme Problems</td><td>6 (1.4%)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Patients reporting complications, including: neuropathy, foot ulcer, amputation, cardiovascular disease, proteinuria, retinopathy, blindness. <sup>b</sup> The EQ-VAS scale is 0 to 100. <sup>c</sup> The EQ-5D scale is &#x02212;&#x02009;0.594 to 1. <italic>BMI</italic> Body Mass Index, <italic>HbA</italic><sub><italic>1c</italic></sub> glycated hemoglobin, <italic>HADS</italic> Hospital Anxiety and Depression Score, <italic>BP</italic> Blood pressure, <italic>EQ-5D</italic> EuroQol 5-Dimension, <italic>EQ-VAS</italic> Visual Analogue Component of the EQ-5D instrument</p></table-wrap-foot></table-wrap></p><sec id="Sec6"><title>Individual EQ-5D dimensions</title><p id="Par23">With regard to individual dimension scores, patients reported very few problems in the mobility and self-care dimensions (89.7% and 95.2%, respectively). In the dimensions reporting usual activities, pain/discomfort, and anxiety/depression, the number of patients reporting no problems was smaller (81.0%, 78.3%, and 70.4%, respectively). Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> provides more detail on the scores for each dimension.<fig id="Fig1"><label>Fig. 1</label><caption><p>Percentage of patients reporting each level of EQ-5D dimension scores. Level 1 represents &#x02018;No Problems&#x02019;, level 2 &#x02018;Some Problems&#x02019;, and level 3 &#x02018;Extreme Problems&#x02019;</p></caption><graphic xlink:href="12955_2018_848_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec7"><title>Multivariate regression results</title><p id="Par24">Multivariate regression results for EQ-VAS scores (scale 0-100) indicated that age, HbA<sub>1c</sub>, disease duration, and obesity (BMI&#x02009;&#x02265;&#x02009;30&#x000a0;kg/m<sup>2</sup>) were significantly associated with patients&#x02019; HRQoL (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Patients&#x02019; age had the smallest impact and obesity had the largest impact on EQ-VAS scores (0.21 ((95% CI: 0.04-0.39) and &#x02212;&#x02009;11.8 (95% CI: -17.2, &#x02212;&#x02009;6.3), respectively. Multivariate regression models were estimated to explore associations with EQ-5D index scores found that self-reported mental illness, and employment status, were significantly and negatively associated with EQ-5D index scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 for both). Self-reported mental illness was associated with a reduction in EQ-5D index&#x000a0;scores (scale 0-1) of approximately &#x02212;&#x02009;0.22 (95% CI: -0.34, &#x02212;&#x02009;0.10) and being unemployed was associated with a reduction of approximately &#x02212;&#x02009;0.07 (95% CI: -0.13, &#x02212;&#x02009;0.02) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). As a sensitivity analysis, EQ-5D respondents were categorized as having &#x02018;no problems&#x02019; (EQ-5D equal to 1) or reporting any &#x02018;problems&#x02019; (EQ-5D score less than 1) and a multivariate logistic regression analysis was conducted. The results of this analysis suggest that self-reported mental illness had the largest and statistically significant effect on reporting of problems with EQ-5D scores; that is, patients with self-reported mental illness were 8 times more likely to report problems in EQ-5D scores (<italic>p</italic>&#x02009;=&#x02009;0.049). Mental illness was significantly associated with an increased likelihood of reporting problems in both the &#x02018;Pain/Discomfort&#x02019; and &#x02018;Anxiety/Depression&#x02019; domains (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), and was not significantly associated with other domains. In addition, being unemployed was associated with an increased likelihood of reporting problems in the &#x02018;Mobility&#x02019;, &#x02018;Self-Care&#x02019;, and &#x02018;Pain/Discomfort&#x02019; domains (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Regression analysis of baseline data with EQ-5D index scores (scale 0-1) as the outcome variable</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Estimate</th><th>95% LL</th><th>95% UL</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Age</td><td>&#x02212;0.001</td><td>&#x02212;&#x02009;0.004</td><td>0.001</td><td>0.132</td></tr><tr><td>Gender (Male)</td><td>&#x02212;0.011</td><td>&#x02212;&#x02009;0.052</td><td>0.029</td><td>0.568</td></tr><tr><td>Unemployed</td><td>&#x02212;0.073</td><td>&#x02212;0.130</td><td>&#x02212;&#x02009;0.016</td><td>0.039</td></tr><tr><td>Obese<sup>a</sup></td><td>&#x02212;0.046</td><td>&#x02212;0.107</td><td>0.014</td><td>0.167</td></tr><tr><td>Medical Card</td><td>&#x02212;0.040</td><td>&#x02212;0.093</td><td>0.014</td><td>0.177</td></tr><tr><td>Marital Status (Single)</td><td>0.011</td><td>&#x02212;0.032</td><td>0.055</td><td>0.580</td></tr><tr><td colspan="5">Education<sup>b</sup></td></tr><tr><td>&#x02003;Complete 2nd level</td><td>0.010</td><td>&#x02212;0.057</td><td>0.077</td><td>0.801</td></tr><tr><td>&#x02003;Complete 3rd level</td><td>0.014</td><td>&#x02212;0.052</td><td>0.080</td><td>0.721</td></tr><tr><td>Complications<sup>c</sup></td><td>&#x02212;0.020</td><td>&#x02212;0.073</td><td>0.032</td><td>0.407</td></tr><tr><td>Disease Duration</td><td>&#x02212;0.002</td><td>&#x02212;0.004</td><td>0.000</td><td>0.095</td></tr><tr><td>Mental Illness<sup>d</sup></td><td>&#x02212;0.219</td><td>&#x02212;0.337</td><td>&#x02212;&#x02009;0.100</td><td>0.017</td></tr><tr><td>High Blood Pressure<sup>d</sup></td><td>&#x02212;0.009</td><td>&#x02212;0.063</td><td>0.044</td><td>0.740</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>&#x02212;0.018</td><td>&#x02212;0.033</td><td>&#x02212;&#x02009;0.002</td><td>0.076</td></tr><tr><td>Heart Disease<sup>d</sup></td><td>0.013</td><td>&#x02212;0.103</td><td>0.129</td><td>0.886</td></tr><tr><td>Chest/Lung Disease<sup>d</sup></td><td>0.051</td><td>&#x02212;0.073</td><td>0.176</td><td>0.491</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> BMI&#x02009;&#x02265;&#x02009;25&#x000a0;kg/m<sup>2</sup>. <sup>b</sup> Reference Category: did not complete second level education. <sup>c</sup> Patients reporting complications, including: neuropathy, foot ulcer, amputation, cardiovascular disease, proteinuria, retinopathy, blindness. <sup>d</sup> Categorical variable (Yes&#x02009;=&#x02009;1, No&#x02009;=&#x02009;0), self-reported. <italic>LL</italic> Lower limit of 95% confidence interval. <italic>UL</italic> Upper limit of 95% confidence interval</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec8"><title>Discussion</title><p id="Par25">This study sought to explore associations between characteristics of Type 1 diabetes patients, with scores from a generic, preference-based measure of HRQoL, the EQ-5D. The importance of performing such exploratory analyses and understanding associations between patient characteristics and EQ-5D scores is two-fold. First, EQ-5D scores are often used in economic evaluations that inform reimbursement decisions for new health interventions. As such, it is important to understand the individual patient characteristics which form the basis for these scores. Second, individual EQ-5D dimension scores can be used to identify which dimensions have the greatest impact on patients&#x02019; overall HRQoL and these dimension scores might allow clinicians to understand where improvements could be made in patient care. The results of this study suggest many Type 1 diabetes patients do not report that their disease has an impact on their individual HRQoL, but, for a subset of Type 1 diabetes patients, mental illness (self-reported) has a statistically significant negative impact on HRQoL.</p><p id="Par26">The results of the EQ-5D presented in this study might suggest that this generic measure of preference-based HRQoL may not be sufficiently sensitive to capture the impact of Type 1 diabetes on patients. However, it is worth noting that a five&#x000a0;level version of the EuroQol instrument (EQ-5D-5L) has been developed to address the issue of sensitivity (as well as other issues) [<xref ref-type="bibr" rid="CR18">18</xref>]. The descriptive system associated with the EQ-5D-5L is an obvious improvement to the EQ-5D-3L, but there remain issues about the tariffs used to estimate index scores, and how these calculations impact the results of cost-utility analyses [<xref ref-type="bibr" rid="CR19">19</xref>]. Accordingly, there has been some reluctance from decision-making bodies to move toward recommending the EQ-5D-5L as a part of reimbursement submissions [<xref ref-type="bibr" rid="CR20">20</xref>]. Similarly, the results reported in this study may have implications for the economic evaluation and reimbursement of new health technologies for individuals with diabetes. For example, if a new technology is put forward to be evaluated for reimbursement, unless it has the ability of improve patients&#x02019; mental health, and thus improve patients&#x02019; responses in the respective domains, it may not show any benefit for a given cost, and is potentially unlikely to be reimbursed. It also suggests that interventions targeting patients&#x02019; mental health are an avenue to improve their HRQoL. This result aligns with findings by Byrne et al. [<xref ref-type="bibr" rid="CR21">21</xref>], whereby their analysis suggested that patients with higher levels of diabetes-related anxiety were most likely to benefit from support programs in terms of improved overall quality of life.</p><p id="Par27">This study has several limitations. First, we used cross-sectional data from a previously completed trial to evaluate associations between HRQoL and potential influential factors. While it is certainly advantageous to use longitudinal data, we emphasize that this study was meant to be exploratory and form a basis for future research. Second, EQ-5D scores were asymmetrically distributed and, as such, pose concerns for standard regression techniques. However, we believe the techniques used to minimize the impact of these concerns are appropriate, particularly in the context of an exploratory study. Third, the presence of mental illness (and other comorbidities) was based on self-report. We acknowledge that a more robust ascertainment of clinical history would be an improvement, as would greater specificity as to the nature of mental illness.</p></sec><sec id="Sec9"><title>Conclusions</title><p id="Par28">Type 1 diabetes patients enrolled in this study reported a high health-related quality of life, with over half of patients reporting &#x02018;perfect&#x02019; health based on EQ-5D responses. However, in those that did report problems, the most common were reported in the &#x02018;Anxiety/Depression&#x02019; dimension. Similarly, multivariate regression analysis suggested that self-reported mental illness had the most substantial impact on EQ-5D scores. The results of this study demonstrate the importance of exploring individual dimensions of EQ-5D scores and the findings may also imply that clinicians treating patients with Type 1 diabetes should be particularly mindful of their patients mental well-being.</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec10"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12955_2018_848_MOESM1_ESM.tiff"><label>Additional file 1:</label><caption><p>CONSORT Flow Diagram for the original cluster randomized controlled trial. (TIFF 6514 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BMI</term><def><p id="Par6">Body mass index</p></def></def-item><def-item><term>CI</term><def><p id="Par7">Confidence interval</p></def></def-item><def-item><term>DAFNE</term><def><p id="Par8">Dose&#x000a0;Adjustment for Normal Eating</p></def></def-item><def-item><term>EQ-5D-3L</term><def><p id="Par9">EuroQol 5-dimesion 3-level</p></def></def-item><def-item><term>HbA<sub>1c</sub></term><def><p id="Par10">Glycated hemoglobin</p></def></def-item><def-item><term>HRQoL</term><def><p id="Par11">Health-related quality of life</p></def></def-item><def-item><term>IQR</term><def><p id="Par12">Interquartile range</p></def></def-item><def-item><term>SD</term><def><p id="Par13">Standard deviation</p></def></def-item><def-item><term>VAS</term><def><p id="Par14">Visual analogue scale</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s12955-018-0848-4) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We wish to thank the all of the patients and DAFNE educators&#x000a0;involved in this study and the Irish DAFNE Study Steering Group: Sean Dinneen (Principal Investigator), Mary Clare O&#x02019;Hara (Project Manager), Lisa Daly (former Project Manager), Simon Heller, C Hamish Courtney, Donal O&#x02019;Shea, Diarmuid Smith, Colm McGurk, Kathy Murphy, Eamon O&#x02019;Shea, Dympna Casey, Julia Lawton, Florence Findlay White, John Newell, Molly Byrne, Paddy Gillespie, Marie Clark, and Debbie Cooke.</p><sec id="FPar1"><title>Funding</title><p id="Par29">The Irish DAFNE RCT was funded by a Health Research Board Health, Services Research and Development Award. Support for this work was also provided by Science Foundation Ireland and the European Regional Development Fund (Grant Number 13/RC/2073). The funders played no part in the design, data analysis, manuscript preparation, nor publication decisions.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par30">Please contact the corresponding author for data requests.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>AR, MG, and PG conceptualized the study. MCOH and SD provided critical insight into the clinical area. All authors were involved in interpreting the study results and contributed to the preparation of the manuscript and subsequently approved the final version.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par31">Ethical approval was obtained from the Research Ethics Committee of Galway University Hospitals (CA 19), from COREC (currently: National Research Ethics Service) Northern Ireland (06/NIR01/126). All study participants provided informed consent prior to enrolment in the trial.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par32">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par33">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par34">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname><given-names>CC</given-names></name><name><surname>Dahlquist</surname><given-names>GG</given-names></name><name><surname>Gy&#x000fc;r&#x000fc;s</surname><given-names>E</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Solt&#x000e9;sz</surname><given-names>G</given-names></name><collab>Group ES</collab><etal/></person-group><article-title>Incidence trends for childhood type 1 diabetes in Europe during 1989&#x02013;2003 and predicted new cases 2005&#x02013;20: a multicentre prospective registration study</article-title><source>Lancet</source><year>2009</year><volume>373</volume><issue>9680</issue><fpage>2027</fpage><lpage>2033</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60568-7</pub-id><pub-id pub-id-type="pmid">19481249</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>MA</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name><name><surname>Michels</surname><given-names>AW</given-names></name></person-group><article-title>Type 1 diabetes</article-title><source>Lancet</source><year>2014</year><volume>383</volume><issue>9911</issue><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60591-7</pub-id><pub-id pub-id-type="pmid">23890997</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Drummond</surname><given-names>MF</given-names></name><name><surname>Sculpher</surname><given-names>MJ</given-names></name><name><surname>Claxton</surname><given-names>K</given-names></name><name><surname>Stoddart</surname><given-names>GL</given-names></name><name><surname>Torrance</surname><given-names>GW</given-names></name></person-group><source>Methods for the economic evaluation of health care Programmes</source><year>2015</year><publisher-loc>Oxford</publisher-loc><publisher-name>University Press</publisher-name><fpage>461</fpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redekop</surname><given-names>WK</given-names></name><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Rutten</surname><given-names>GE</given-names></name><name><surname>Wolffenbuttel</surname><given-names>BH</given-names></name><name><surname>Niessen</surname><given-names>LW</given-names></name></person-group><article-title>Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><issue>3</issue><fpage>458</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.3.458</pub-id><pub-id pub-id-type="pmid">11874930</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danyliv</surname><given-names>A</given-names></name><name><surname>Gillespie</surname><given-names>P</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>C</given-names></name><name><surname>Noctor</surname><given-names>E</given-names></name><name><surname>O&#x02019;Dea</surname><given-names>A</given-names></name><name><surname>Tierney</surname><given-names>M</given-names></name><etal/></person-group><article-title>Health related quality of life two to five years after gestational diabetes mellitus: cross-sectional comparative study in the ATLANTIC DIP cohort</article-title><source>BMC Pregnancy Childbirth</source><year>2015</year><volume>15</volume><issue>1</issue><fpage>274</fpage><pub-id pub-id-type="doi">10.1186/s12884-015-0705-y</pub-id><pub-id pub-id-type="pmid">26496985</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>K</given-names></name><name><surname>Loar</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>BJ</given-names></name><name><surname>Heptulla</surname><given-names>RA</given-names></name></person-group><article-title>The role of socioeconomic status, depression, quality of life, and glycemic control in type 1 diabetes mellitus</article-title><source>J Pediatr</source><year>2006</year><volume>149</volume><issue>4</issue><fpage>526</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2006.05.039</pub-id><pub-id pub-id-type="pmid">17011326</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname><given-names>S</given-names></name><name><surname>Amiel</surname><given-names>SA</given-names></name><name><surname>Rogers</surname><given-names>H</given-names></name><name><surname>Choudhary</surname><given-names>P</given-names></name><name><surname>Cox</surname><given-names>A</given-names></name><name><surname>de Zoysa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Poorer glycaemic control in type 1 diabetes is associated with reduced self-management and poorer perceived health: a cross-sectional study</article-title><source>Diabetes Res Clin Pract</source><year>2014</year><volume>106</volume><issue>1</issue><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2014.07.023</pub-id><pub-id pub-id-type="pmid">25128266</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>HE</given-names></name><name><surname>Bilo</surname><given-names>HJG</given-names></name><name><surname>Redekop</surname><given-names>WK</given-names></name><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Assink</surname><given-names>JH</given-names></name><name><surname>Jong</surname><given-names>BM</given-names></name></person-group><article-title>Quality of life of patients with type I diabetes mellitus</article-title><source>Qual Life Res</source><year>2003</year><volume>12</volume><issue>8</issue><fpage>1089</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1023/A:1026197119569</pub-id><pub-id pub-id-type="pmid">14651426</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQueen</surname><given-names>RB</given-names></name><name><surname>Ellis</surname><given-names>SL</given-names></name><name><surname>Maahs</surname><given-names>DM</given-names></name><name><surname>Anderson</surname><given-names>HD</given-names></name><name><surname>Nair</surname><given-names>KV</given-names></name><name><surname>Libby</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Association between Glycated hemoglobin and health utility for type 1 diabetes</article-title><source>Patient</source><year>2014</year><volume>7</volume><issue>2</issue><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s40271-014-0045-4</pub-id><pub-id pub-id-type="pmid">24458545</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solli</surname><given-names>O</given-names></name><name><surname>Stavem</surname><given-names>K</given-names></name><name><surname>Kristiansen</surname><given-names>IS</given-names></name></person-group><article-title>Health-related quality of life in diabetes: the associations of complications with EQ-5D scores</article-title><source>Health Qual Life Outcomes</source><year>2010</year><volume>8</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1477-7525-8-18</pub-id><pub-id pub-id-type="pmid">20053296</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Irish DAFNE Study Group</collab><name><surname>Dinneen</surname><given-names>SF</given-names></name><name><surname>O&#x02019; Hara</surname><given-names>MC</given-names></name><name><surname>Byrne</surname><given-names>M</given-names></name><name><surname>Newell</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>L</given-names></name><etal/></person-group><article-title>The Irish DAFNE study protocol: a cluster randomised trial of group versus individual follow-up after structured education for type 1 diabetes</article-title><source>Trials</source><year>2009</year><volume>10</volume><issue>1</issue><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-10-88</pub-id><pub-id pub-id-type="pmid">19775465</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinneen</surname><given-names>SF</given-names></name><name><surname>O&#x02019;Hara</surname><given-names>MC</given-names></name><name><surname>Byrne</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Courtney</surname><given-names>CH</given-names></name><name><surname>McGurk</surname><given-names>C</given-names></name><etal/></person-group><article-title>Group follow-up compared to individual clinic visits after structured education for type 1 diabetes: a cluster randomised controlled trial</article-title><source>Diabetes Res Clin Pract</source><year>2013</year><volume>100</volume><issue>1</issue><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2013.01.017</pub-id><pub-id pub-id-type="pmid">23398978</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillespie</surname><given-names>P</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>E</given-names></name><name><surname>O&#x02019;Hara</surname><given-names>M</given-names></name><name><surname>Dinneen</surname><given-names>SF</given-names></name><collab>for the Irish DAFNE Study Group</collab></person-group><article-title>Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial</article-title><source>Trials</source><year>2014</year><volume>15</volume><issue>1</issue><fpage>227</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-15-227</pub-id><pub-id pub-id-type="pmid">24927851</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The EuroQol Group</collab></person-group><article-title>EuroQol - a new facility for the measurement of health-related quality of life</article-title><source>Health Policy</source><year>1990</year><volume>16</volume><issue>3</issue><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/0168-8510(90)90421-9</pub-id><pub-id pub-id-type="pmid">10109801</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolan</surname><given-names>P</given-names></name><name><surname>Gudex</surname><given-names>C</given-names></name><name><surname>Kind</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name></person-group><article-title>The time trade-off method: results from a general population study</article-title><source>Health Econ</source><year>1996</year><volume>5</volume><issue>2</issue><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1099-1050(199603)5:2&#x0003c;141::AID-HEC189&#x0003e;3.0.CO;2-N</pub-id><pub-id pub-id-type="pmid">8733106</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>D</given-names></name><name><surname>Devlin</surname><given-names>N</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name></person-group><article-title>What determines the shape of an EQ-5D index distribution?</article-title><source>Med Decis Making</source><year>2016</year><volume>36</volume><issue>8</issue><fpage>941</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1177/0272989X16645581</pub-id><pub-id pub-id-type="pmid">27112934</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gujarati</surname><given-names>DN</given-names></name></person-group><source>Basic econometrics</source><year>2003</year><edition>4</edition><publisher-loc>Boston</publisher-loc><publisher-name>McGraw Hill</publisher-name><fpage>1002</fpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herdman</surname><given-names>M</given-names></name><name><surname>Gudex</surname><given-names>C</given-names></name><name><surname>Lloyd</surname><given-names>A</given-names></name><name><surname>Janssen</surname><given-names>M</given-names></name><name><surname>Kind</surname><given-names>P</given-names></name><name><surname>Parkin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)</article-title><source>Qual Life Res</source><year>2011</year><volume>20</volume><issue>10</issue><fpage>1727</fpage><lpage>1736</lpage><pub-id pub-id-type="doi">10.1007/s11136-011-9903-x</pub-id><pub-id pub-id-type="pmid">21479777</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Alava MH, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, et al. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost-Effectiveness in the United Kingdom. Value Health. 2017. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.valueinhealthjournal.com/article/S1098-3015(17)33410-1/fulltext">http://www.valueinhealthjournal.com/article/S1098-3015(17)33410-1/fulltext</ext-link>. Accessed 15 Dec 2017.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence (NICE)</collab></person-group><source>NICE position statement on use of the EQ-5D-5L valuation set</source><year>2017</year></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>M</given-names></name><name><surname>Newell</surname><given-names>J</given-names></name><name><surname>Coffey</surname><given-names>N</given-names></name><name><surname>O&#x02019; Hara</surname><given-names>MC</given-names></name><name><surname>Cooke</surname><given-names>D</given-names></name><name><surname>Dinneen</surname><given-names>SF</given-names></name></person-group><article-title>Predictors of quality of life gains among people with type 1 diabetes participating in the dose adjustment for normal eating (DAFNE) structured education programme</article-title><source>Diabetes Res Clin Pract</source><year>2012</year><volume>98</volume><issue>2</issue><fpage>243</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2012.09.017</pub-id><pub-id pub-id-type="pmid">23018180</pub-id></element-citation></ref></ref-list></back></article>